Fobi AI Inc. announced that the British Columbia Securities Commission has fully revoked the cease trade order issued in November 2024 due to the company's failure to file its 2024 annual audited financial statements and related documents. Fobi has now filed all overdue 2024 and subsequent financial reports, including corrected interim filings for late 2025. The company is working with the TSX Venture Exchange to reinstate trading of its shares. This development clears a major regulatory hurdle, allowing Fobi to resume normal market activities pending exchange approval.
Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's resear...
Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, ...
Holtec Nuclear Corporation has filed a registration statement with the U.S. SEC for a proposed initial public offering (IPO) of its Class A common stock, planning to list on Nasdaq under the symbol "HNUC." The offering details, including share count ...
Halper Sadeh LLC is investigating whether shareholders of Simulations Plus (SLP), Huntsman Corporation (HUN), Olin Corporation (OLN), and Pulmatrix (PULM) are receiving fair deals in recent mergers and sales. The firm suspects insiders may gain finan...
XRP has shown signs of recovery after weeks below a descending resistance line, rebounding from a late-June low near $1.00. It is currently testing a key resistance at $1.12, where a breakout could indicate weakening seller control and lead to furthe...
